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ABSTRACT  
Aims : To investigate on the relationship between the  severity of ketoacidosis, an important risk 
factor for C-peptide preservation, and  long-term microvascular complications in childhood-onset 
type 1 diabetes mellitus (T1DM).  
Methods: 230 childhood-onset diabetic patients (177 pre-pubertal), aged  7.0±3.8 years followed 
for at least 15 yrs after their diagnosis, were enrolled. Clinical and laboratory data at diagnosis, and 
C-peptide levels in a subset of patients, were compared with the severity of retinopathy and 
nephropathy, after a mean of 19.6±3.8  years of disease. Digital retinal photographs were taken in 
all patients, and centrally graded. Repeated measurements of HbA1c and microalbuminuria for the 
whole duration of diabetes were collected in over half of the cases. 
Results: Out of  230 patients, those with the lowest age at diagnosis had the most severe DKA and  
clinical conditions  (p<0.05), and lower C-peptide levels (p<0.0001) at diagnosis. There was a 
significant relationship between pH and clinical severity ((r= - 0.783, p<0.0001), and between pH  
and C-peptide levels (r= 0.278, p<0.05). The severity of ketoacidosis had no relationship with 
subsequent lifetime HbA1c values and long-term microvascular complications. In logistic 
regression analysis, the only variables that independently influenced severity of retinopathy were 
lifetime HbA1c (B=0.838, p<0.001),  duration of disease (B= 0.208, p<0.005) and age at diagnosis  
(B=0.116, p<0.05).  
Conclusions: The degree of metabolic derangement at diagnosis is not associated with retinopathy 
and nephropathy in childhood-onset T1DM.  Age at diagnosis seems to be an important variable to 
be considered when evaluating the long-term effects of residual beta-cell function.  
 
 
 
Keywords: ketoacidosis, childhood-onset diabetes,  retinopathy, nephropathy, C-peptide, HbA1c 
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1. INTRODUCTION 
The occurrence of DKA in children with newly diagnosed type 1 diabetes mellitus (T1DM)  is still 
high, especially in younger children [1-3] and has not significantly changed over time sometimes 
despite the efforts of  information programs [4] . Younger age, lack of private health insurance, 
ethnic minority status and no family history of T1DM are independently predictive of DKA [3,5]. 
While there are no doubt on the fact that DKA is acute life-threatening complication, data about its 
relationships with future long-term complications are lacking. The identification of this relationship 
may be relevant, since the degree of metabolic derangement at diagnosis may partly reflect the 
degree of the residual beta-cell function  [1,6,7] that, according to some authors [8-10],  is, in turn, 
associated with the risk of late complications. In contrast, other authors refute the  hypothesis of this 
link [11,12], or, at most, its effects would be indirectly mediated by  improved metabolic control 
[13,14].  Even more uncertain is the future of the patients with younger age at diagnosis and low  
levels of C-peptide [2,15], since they are little  represented in the various studies,  despite the fact 
that TIDM in this age range is increasing [16] .  In a previous study of our group [17]  we reported 
that, if diabetes is diagnosed in infant or toddlers  and  the  prepubertal duration is the longest, the 
patients seem to be protected against the risk of microvascular complications.  
In the present study we aimed to verify whether the severity of metabolic derangement at diagnosis 
in childhood-onset T1DM is  predictive of long-term micro-vascular  complications 20 years later. 
The majority of cases included in the study were prepubertal children and to our knowledge, a long-
term outcome in a higher number  of very young children   has not been reported in other studies. 
 
2. MATERIALS AND METHODS 
This is a multicenter retrospective cohort study  involving 11 pediatric units in Italy with current 
cross-sectional data on retinal and renal complications.   
The patients were recruited among those who were diagnosed with T1DM as children between 1981 
and 1992 and were included in the study according these criteria: each participating centre has 
attempted to trace all  cases of T1DM who had been diagnosed between 1981 and 1992,  i.e., with 
at least 15 years of disease, and who had been transferred to adult care at the time of study. If year 
by year at least 60% of the original cohort  was tracked down, then all  tracked patients , with 
diagnosis in that year, were included in the study. Otherwise, if the percentage of the tracked 
patients was lower, all the participants with onset in that year, tracked from that centre, were 
excluded. 
In total, 230 caucasian patients (115 males/115 females, 177 prepubertal (77%) defined by Tanner 
stage), aged 7.0 ±3.8 years at diagnosis (range 0.8–14.9 yrs; n.84 aged <5 yrs) were enrolled. All 
4 
 
patients but six showed at least one autoantibody at diagnosis among ICA,  and anti-insulin 
antibodies, and  the diagnosis was confirmed during follow-up by the clinical course of the patient 
and the insulin requirement leading to total insulin dependence within 2 years. The few cases 
without autoantibodies or  with wide fluctuations in the need for insulin were screened for possible 
mutation in the glucokinase, HNF1A and HNF4A  genes, and found negative. Ninety-nine patients 
were diagnosed between 1982 and 1989 and 131 between 1990-1992. Over this time period most 
patients changed insulin regimens switching from  2 to 3 or more daily insulin injections and from 
human insulin to analog insulins starting from 1984. Mean diabetes duration was 19.6 ±3.8 (range 
15–28.5), being 20 years or more in 80 cases. Patients  were recalled between 2007 and 2009 to 
perform retinal photography and to retrieve clinical and laboratory data at diagnosis and during 
follow-up from existing clinical records. . A subset of this cohort has been studied in our recent 
study [17] .  
 
2.1 At diagnosis 
Severity of disease at onset was categorized according to pH levels and clinical presentation (Table 
1): grade 1 (n=22) asymptomatic and/or serendipitous diagnosis; grade 2 (n=102) polyuria and 
polydipsia together with good general clinical conditions; grade 3 (n=71) severely compromised 
clinical conditions with Kussmaul’ respiration and manifest signs of  dehydration; grade 4 (n=34) 
impaired consciousness to coma. Ketoacidosis was defined as capillary pH ≤7.30. Glycemic values 
were available in all but 11 patients, capillary pH value in 178 patients, basal fasting C-peptide 
levels in 117 and C-peptide levels after glucagon or test meal stimulation in 70 of them, performed 
only in some centers. The cases who had C-peptide measurements were not different from those 
who did not have, as regards the clinical and laboratory features at diagnosis.   C-peptide 
measurements was performed during the first admission between the  3rd and the 7th day after the 
diagnosis, once the acute metabolic derangement was resolved.   C-peptide was measured by 
radioimmunoassay using kits (Bio-Rad, Richmond, CA and Technogenetics, Lisophase, Milan, 
Italy ) with lower limits of detection varying between 0.03 and 0.10 nmol/L. To compare data from 
different laboratories, we arbitrarily assigned scores to the C-peptide levels reported  (Table 1): 
score 1 (n=23) undetectable or below 0.03 nmol/L, the lowest limit of detection of the kits, and also 
of the C-peptide RIA used in the DCCT; score 2 (n=32) between 0.03 and 0.10 nmol/L, i.e. under 
the lower limit of detection of some other kits; score 3 (n=29 cases) minimal secretion between 0.11 
and 0.20 nmol//L; score 4 (n=33 cases)  moderate secretion, above 0.20 nmol/L, as used in the 
DCCT [5] as cut off for stimulated C-peptide.  
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2.2 Follow-up  
Repeated measurements of HbA1c for the whole duration of diabetes were available for 135 
patients (Table 2). HbA1c had been measured by different methods (Bio-Rad minicolumn, high-
performance liquid chromatography, or DCA 2000 analyzer). To compare results from different 
laboratories, the values were transformed into percentages of HbA1c above the upper normal 
reference value of each laboratory. Values were averaged throughout the entire duration of disease 
(excluding the value at diagnosis) and also in separate clusters for the years 0–5, 5–10,10–15, 15–
20, and 20–25.  
Digital retinal photographs were taken in mydriasis of two 50° fields per eye, one centered on to the 
macula and the other nasally to the disc, according to the EURODIAB protocol [18] . The pictures 
were centrally graded in the Diabetic Retinopathy Centre of the Department of Medical Sciences at 
Turin University by a trained reader. The pictures were graded according to a 5 degree severity 
scale based upon the American Academy of Ophthalmology simplified classification [19], from no 
diabetic retinopathy (DR) (Grade 1), to mild nonproliferative DR (2), moderate nonproliferative DR 
(3), severe nonproliferative DR (4), and proliferative DR (5). For statistical purposes, all patients 
with grades 3, 4 and 5 were grouped together as moderate-to-severe DR. 
Data on repeated measurement of urinary albumin excretion (UAE) during follow-up and at the 
time of retinal photography were available in 168 patients. Microalbuminuria was defined as UAE 
between 30 and 300 mg/24 h or as albumin excretion rate (AER) ≥20 ug/min; macroalbuminuria as 
UAE >300mg/day or AER >150µg/min. 
This study was performed in accordance with the Declaration of Helsinki as revised in the year 
2000 and approved in the participating centers by an Institutional Review Board regulating non-
interventional studies. Written informed consent was obtained from each patient or parent.  
2.3 Statistical analysis 
All statistical analyses were carried out using the SPSS (Statistical Package of Social Sciences, 
Chicago, IL, USA) for Windows software program version 14.0.1. Data distribution was analyzed 
by skewness and kurtosis coefficients and the Kolmogorov-Smirnov test. Where applicable, normal 
distribution was obtained after logarithmic or square root transformation. For normally distributed 
data statistical significance was assessed using one-way analysis of variance for multiple 
comparisons (Bonferroni test), Student’s unpaired t-test and Pearson’s correlation index. The 
multifactorial model was evaluated using stepwise logistic regression analysis. For non-normally 
distributed data Kruskal-Wallis and Mann-Whitney tests and Spearman correlation index computed 
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on the ranks were used. Pearson chi-square, Yates’ continuity correction and  Fisher s exact tests 
for nominal variables were used. A p less than 0.05 was considered significant. 
3. RESULTS  
 
Out of 230 patients, 46% were in severe clinical conditions (grade 3-4) at diagnosis and 15% were 
in a state of impaired consciousness or in a coma; 56% had any form of ketoacidosis and 21% had  
a severe DKA with a blood pH value <7.10 (Table 1). There was an high correlation between the 
severity score and pH (r= - 0.783, p<0.0001). In the patients <5 years the occurrence of a more 
severe clinical decompensation and  severe DKA  was significantly (p< 0.05) higher than that of 
patients >5yrs  (24% vs 9%, p<0.025, and 29% vs 16%, p<0.05, respectively). The younger  
patients , also , showed lower basal C-peptide levels at diagnosis (r=0.361, p<0.0001).  Among the 
patients <3yrs, 4% belonged to the category with highest C-peptide levels, compared to 85% in the 
lowest categories 1 and 2: the difference was significant (p<0.0001). There was a significant 
correlation between basal C-peptide levels  and pH (r=0.279, p<0.05),  clinical score (r= -0.354, 
p<0.0001), and stimulated C-peptide values (r=0.69, p<0.0001) at diagnosis. The duration of 
disease and mean levels of HbA1c at 5 years and lifetime were similar for all gravity scores and C-
peptide groups. The degree of metabolic decompensation and C-peptide levels  at diagnosis were 
not significantly related to HbA1c values, both lifetime and subdivided by five-years groups.  
After almost 20 year duration, the prevalence of any DR was 55% (n=127 out of 230). Of these, 93 
patients (40%) had grade 2 DR; 20 (8.7%) had grade 3; 8 (3.5%) had grade 4 and 6 (2.6%) had 
grade 5 (Table 2). Among the 34 patients with moderate to severe DR  five (15%) were aged  <3 
years, and 15 (44%) >9 yrs at diagnosis.   Table 3 show the relationships between DR and all the 
main variables.  Severity of DR increased with age at diagnosis (p<0.025), longer duration of 
disease (p<0.0001) and higher HbA1c, either lifetime (p<0.025) or within each 5 year time interval. 
On the contrary, the presence and severity of DR were not related to the variables at diagnosis, such 
as blood pH values, clinical severity score, basal C-peptide levels (Table 3), C-peptide levels after 
stimulation, glycaemia and base excess. No relationships were found even when adjusted for 
different age-groups.  Furthermore, the 34 patients with the best clinical conditions at diagnosis 
(absence of symptoms or ketoacidosis  and presence of detectable C-peptide) did not differ from the 
30 worst ones at diagnosis (coma or impaired consciousness, severe ketoacidosis and undetectable 
C-peptide levels) by DR severity after 20 years, patients without DR being 47% vs 57% and those 
with severe DR being 15% vs 7%, respectively. In logistic regression analysis, the only variables 
that independently influenced retinopathy were lifetime HbA1c (B= 0.838, p<0.001), duration of 
disease (B= 0.208, p< 0.005) and age at diagnosis (B= 0.116, p<0.05). 
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Twelve (7.2%) out of the patients studied for renal function had abnormal value: 8 had 
microalbuminuria (4.8%), 3 had macroalbuminuria (1.8%) and one had end-stage disease with renal 
transplant (0.6%). Three out of these last 4 patients with overt nephropathy  had more than 9 years 
at diagnosis. Proliferative DR was present in 3 of them (1 with microalbuminuria, 1 with macro and 
1 with renal transplant). Five patients with microalbuminuria had no DR, 2 with micro and 1 with 
macroalbuminuria had DR grade 2 and 1 with macroalbuminuria had DR grade 3.  
Patients with nephropathy did not differ significantly from all others by age at diagnosis, duration of 
disease, severity of ketoacidosis, clinical conditions, and basal C-peptide at diagnosis, or lifetime 
HbA1c. 
4. DISCUSSION 
The main finding of this study is that the severity of metabolic derangement at clinical onset of 
diabetes in childhood predict neither presence nor severity of retinopathy or nephropathy, as 
assessed 20 years later.  
The 56% prevalence of all forms of DKA at diagnosis in the present study  results higher than that 
reported in other studies [3,4,20], but this difference may partly be due to variability of some 
parameters considered in the studies, as calendar years of diagnosis,  age range, definitions of DKA, 
as pH <7.25, <7.30, ≤7.30, from venous, arterial, or capillary blood. The prevalence of 15% of 
severe DKA with impaired consciousness or coma, is, instead,  more similar to the findings of other 
studies, according to which this percentage amounted between one-sixth and one-fifth of all patients 
and is not falling significantly over the years [5,20,21]. Our data confirm well-known findings that 
younger children are characterized  by more severe metabolic derangement at diagnosis [1, 3-5, 22]   
and lower C-peptide levels [2,15]. Younger age and ketoacidosis at diagnosis have been reported, in 
turn, as the stronger predictors of loss of residual beta-cell function at 12 [1,7, 15]  and 24 months 
[6], so that, has been hypothesized [7] that the high occurrence of DKA and the low rate of partial 
remission in youngest children may reflect more aggressive beta-cell destruction in these patients. 
Furthermore, beta-cell function has been related in adult or adolescent patients, on later glycemic 
control [8,23], even if is not well clear whether sustained  C-peptide levels are the cause or the 
consequence of good control, since high blood glucose is toxic to beta cells [24]. We have failed to 
find an predictive association between the degree of metabolic decompensation  or C-peptide levels 
at diagnosis and subsequent HbA1c values. This is in agreement with recent  studies [1,25] 
examining, as our study, only pediatric patients and evaluating C-peptide levels at or near  
diagnosis.  
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The prevalence of any DR (55%) and severe DR (6%)   is comparable with European studies [26]  
but lower than that found in American studies [27] in cases with similar age at diagnosis and 
duration of disease.  Our findings, summarized in Table 3,  confirm that  long disease duration, 
higher age at diagnosis [13,28,29] and  lifetime metabolic control [23,30] play a significant role in 
the risk of micro-vascular complications, whereas, similar to previous reports [11,12],  severity of 
metabolic derangement or C-peptide levels at diagnosis do not play any role.   This result is 
supported by the  finding that  the two subsets of patients with the best and worst conditions at 
diagnosis, have  a similar long-term outcome, and although the number of these selected patients is 
limited, the result seems noteworthy. Additional evidences for the lack of association between DKA 
at diagnosis and microvascular complications may be found in the finding that the patients with 
higher age at diagnosis had both best clinical conditions along with higher C-peptide levels at 
diagnosis and higher risk for retinopathy, while those with younger age had higher incidence of 
ketoacidosis, along with lower C-peptide levels and lower prevalence of DR.  Other studies, on the 
contrary, reported opposite results, supporting a link  between beta-cell function and long-term 
complications [9,10], which may be exerted indirectly, through better metabolic control [9,13].  
DCCT study [23] seems confirm this latter hypothesis, since the significant difference in the risk of 
complications between C-peptide groups disappeared after adjusting for hemoglobin A1c value. 
However, these studies  involved  adult or adolescent patients, while our cohort is strictly pediatric, 
consisting in large part  of very young children, 84 cases below 5 years of age. The difference in 
age could be the main cause of these discordant results, as residual beta-cell secretion in children is 
typically small and rapidly exhausted over the first years of diabetes [15,31,32], probably due to 
lower beta-cell mass than adults [33].  In adults and  adolescents, in contrast,  C-peptide levels are  
easily  detectable also after tens of years of disease [10,34], and in fact  Nakanishi et al. [13] 
suggested  that prolonged preservation of detectable C-peptide for at least 10 years  is needed to 
confer clinically meaningful benefits on risk of DR, and such a length is unimaginable in the most 
cases of very young children.  
Our data confirm that nephropathy is less frequent than DR. The prevalence in our cases is the 
same, 7%, as in our previous report including about half this cohort [17] but lower than reported in 
other studies [28]. The patients with nephropathy did not differ significantly from all others for any 
of the variables considered, although the most severe cases were older at diagnosis, according to 
what we reported in our previous study [35]. However statistical power deriving from their low 
numbers does not allow to speculate. 
Strengths of this study include 1) availability of long-term follow-up of the largest cohort (177 
cases) of prepubertal children at diagnosis, 53 of whom <3 years, compared to previous studies, 2) 
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homogeneity  for calendar period of onset and disease duration, 3) information on biochemical 
and/or clinical  conditions at diagnosis in all participants, 4) assessment of  retinal photography in 
all tracked patients along with centralized grading of the pictures  by a single independent observer. 
Limits include the following: 1) availability of basal C-peptide determinations in only about half of 
the subjects and of stimulated values in just over half of these, and the lack of  follow-up C-peptide 
measurements. Actually, a single assessment of C-peptide status at the time of diagnosis may not 
represent a true reflection of patients who will versus those who will not go through the partial 
remission phase, and the degree of preservation of residual beta-cell function well beyond diagnosis 
may be more important.  We care caution to consider the severity of metabolic derangement at 
diagnosis as synonymous of the level of residual beta-cell function.  However, the finding reported 
in literature [1,2,6],  that DKA is  an important risk factor for C- peptide preservation at 12 and 24 
months, a doubt on the existence of this link may be raised; 2) the majority of our patients were 
prepubertal and the effects of age could mask the beneficial effect of  basal C-peptide, as the 
younger age at diagnosis is independently associated with a protective effect on DR. However, even 
when the influence of age is excluded, considering separately each age group, the prevalence of DR 
remain similar in each clinical severity and C-peptide subgroup; 3) missing HbA1c might be argued 
as selection bias in contributing with patients with lower HbA1c. However, the missing values are 
mainly due to the difficulties in some centers to collect data from old clinical chart for unselected 
reasons. Furthermore, our rather good mean values are  not unusual in our Regions and  are fully 
consistent with other Italian [36] or international multicenter studies [37] in which Italian HbA1c 
levels were among the lowest.  
5. CONCLUSIONS 
Even if  these results cannot be generalized to other ethnic groups and to different cohorts of  
patients with worse metabolic control than ours, this study provides evidence that the severity of 
metabolic decompensation at diagnosis is not associated with the presence and severity of long-term 
complications in childhood-onset diabetes, at least in a population of very young patients diagnosed 
20-30 years ago. Although this is not necessarily applicable to the decline in residual beta-cell 
function after diagnosis, our data seem to suggest that  the long-term effects of residual beta-cell 
function can be very different in patients with young age at diagnosis. By contrast, metabolic 
control during the whole disease duration, seems fundamental in determining microvascular 
complications also in children.  It will be interesting to verify in the next years whether these 
findings are confirmed also  in a cohort of patients diagnosed in the last 10-15 years, i.e. after the 
awareness of the lesson from DCCT and widespread use of analog insulins..  
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Table 1. Patients’ characteristics at diagnosis*  
Patients           
n. 230           
(115 m/115f) 
Prepubertal 
n.                    177                                            
Pubescent 
37
Pubertal** 
15 
7.0 ± 3.8 (0.8-14.9) Age (yrs)         
n. 230     
 
                  < 3yrs                               
n.                     53 
3-9 yrs                       
104 
>9 yrs                                
73 
1981-1992 Calendar year 
 
1981-1989                                             
n. 99 
1990-1992                                            
n. 131 
Clinical severity 
score                
n. 230                    
 
grade 1 
n.          23                
%  10.0 (6.2-13.8) 
grade 2 
102                    
44.3 (37.9-50.6) 
grade 3 
71                       
30.9 (25.0-36.9) 
       grade 4 
34                           
14.8 (19.6-19.7) 
Blood glucose 
n.219 (mg/dl) 
409 ± 184 (110- 1025) 
Base excess  
n.167 (mmol/L) 
                                             - 10.7 ± 9.2 (-31/+ 8) 
7.23 ± 0.16 (6.71 – 7.48) pH                    
n. 178 
 
<7 
n.       14           
% 7.9 (4.5-12.4)  
7 - 7.10 
24                  
13.5 (9.0-18.9) 
7.10 - 7.20 
21                    
11.8 (7.6-17.0) 
7.20 - ≤7.30 
40                     
22.5 (16.7-28.8) 
> 7.30 
79                      
44.3 (37.0-51.4) 
0.55 ± 0.57 (0.02 – 2.65) Basal C-peptide   
n.117     
(nmol/L) 
≤ 0.03           
(group 1)   
n.        23                   
%  19.7 (13.1-27.3) 
0.04 – 0.10      
(group 2) 
31                         
26.5 (19.0-34.7) 
0.11 – 0.20      
(group 3) 
30                          
25.6 (18.2-33.8) 
> 0.20                 
(group 4)  
33                              
28.2 (20.5-36.5) 
0.9 ± 0.8 ( 0.02 – 3.78) Stimulated C-
peptide        
n.70       
(nmol/L) 
                         ≤ 0.20                                             
n.                         32                                                    
%            45.7 (33.9-56.6) 
> 0.20                                            
38                                          
54.3 (42.0-64.8) 
*Data are expressed as mean ± SD  (range) or as number of cases and percentage with 95% 
confidence intervals in brackets 
** Tanner stages 2 and 5, respectively, are the thresholds for the definition of pubescent and 
pubertal 
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Table 2. Patients characteristics at the time of retinal photography*  
 
Calendar year  2007 – 2009 
Attained age (yrs)             (n=230) 26.6 ± 5.4 ( 16 – 40.3) 
Duration of disease (yrs)  (n=230)               19.6 ± 3.8 ( 15 – 28.5) 
Last HbA1c value (%)     (n=172)  
(percentage above the upper normal range) 
7.9 ± 1.2  (5.3 – 12.8) 
  132.6 ± 22.4  (85 – 213) 
Lifetime HbA1c (%)       (n=132)                     
(percentage  above the upper normal range) 
            7.9 ± 0.8  (6.2 – 9.8) 
                134.2 ± 14.2  (102- 165) 
HbA1c values in the first 5 years of disease   (n=153)                  
(percentage above the upper normal range) 
8.0 ± 1.0 (6.0 – 13.1) 
  134.1 ± 17.1 (100- 226) 
HbA1c values 5-10 years of disease  (n=150) 
(percentage above the upper normal range) 
8.2 ± 1.1 (5.7 – 12.4) 
136.7 ± 24.7 (98- 214) 
HbA1c values 10-15 years of disease (n=165)                  
(percentage above the upper normal range) 
8.1 ± 1.1 (5.9 – 13.1) 
137.7 ± 19.7 (97- 226) 
HbA1c values 15-20 years of disease (n=127)                  
(percentage above the upper normal range) 
7.9 ± 1.2 (5.9 – 13.6) 
   133.1 ± 19.9 (101- 232) 
HbA1c values 20-25 years of disease (n=36)                  
(percentage above the upper normal range) 
            7.8 ± 1.0 (5.9 – 9.6) 
    117.5 ± 38.4 (100- 153) 
n.                                         127/230  
%                                    55.2  (48.5- 61.3) 
Patients with 
diabetic retinopathy   
 
      
      
          grade 2                  
n.          93                    
%  40.4 (34.1-46.7) 
grade 3                           
20                
8.7 (5.5-12.8) 
grade 4                
8                   
3.5 (1.6-6.4) 
grade 5         
6                 
2.6 (1.1-5.3) 
 
n. Patients with abnormal urinary albumin excretion                             
 
n.        12/168                         
%                 7.1 (3.9-11.7) 
 
*Data as mean ± SD (range) or as number of cases and percentage with 95% confidence intervals in 
brackets 
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Table 3. Distribution of the variables, according to presence and severity of diabetic retinopathy 
(DR)*   
 
 
At diagnosis  
pH 
 
≤7.30   > 7.30 
Grade of clinical 
severity 
1      2       3       4 
Basal C-
peptide group 
1+2     3       4 
Age  
(yrs) 
Duration 
of disease 
(yrs) 
Lifetime 
HbA1c (% 
upper 
normal 
reference 
value) 
Without DR 
n.103 
59            41 11    44     28    17 51      18     31 6.1±3.6 18.5 ±3.1 130.8±13.3 
mild DR  
grade 2 
n.93 
56            44 
 
 9     44     36    11 44      29     27 7.4±3.9 20.1±4.0 135.4±13.7 
severe DR 
grade 3+4+5 
n.34 
48            52  9     48     24    18  41     35      24 8.1±3.9 21.9±4.1  140.9±16.1 
     NS                         NS                       NS                p< 0.025      p<0.0001       p<0.025 
 
 
*Data as percentages or means ± SD 
 
 
